BRUSSELS - The
European Medicines Agency (EMA) is preparing to approve Pfizer / BioNTech's anti-Covid vaccine adapted to combat the
BA.4 and BA.5 Omicron variants in the autumn.
This was stated by a spokesman for the same Ema.
The two pharmaceutical companies have started a clinical trial and are expected to submit an authorization application to EMA soon, which could proceed with rapid approval in the fall.